Biomarcadores biológicos en las enfermedades respiratorias

García‐Río, Francisco; Alcázar, Bernardino; Castillo, Diego; Cillóniz, Catia; García-Ortega, Alberto; Leiro-Fernández, Virginia; Lojo-Rodríguez, Irene; Padilla, Alicia; Quezada, Carlos; Rodríguez-Portal, José Antonio; Sánchez‐de‐la‐Torre, Manuel; Sibila, Oriol; Martínez‐García, Miguel Ángel

doi:10.1016/j.arbres.2022.01.003

Cited by 24 publications

(8 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP and fibrinogen are biomarkers associated with increased risk of death and severe COPD exacerbations, while CC16 and sRAGE are biomarkers associated with decreased lung function and progression of emphysema. 25 Levels of miR-320c in serum, which is an inhibitor of SERPINA1 expression, are associated with lung disease in patients with high levels of alpha-1antitrypsin. There is a decrease in the expression of SOD3 and fibulin-5 in COPD patients and an increase in methylated miR-7 levels in emphysema patients.…”

Section: Understanding Genetics and Molecules In Pathogenesismentioning

confidence: 99%

“…Therefore, COPD-specific biomarkers are needed to determine an accurate diagnosis, target therapy, and prognosis. 25 Biomarkers in COPD are being widely studied, but there are difficulties in interpreting research data due to weak association relationships and lack of reproducibility between cohorts. Blood eosinophil biomarkers of more than 300 cells/μL are widely used to determine the risk of exacerbations and assess the response to inhaled corticosteroid (ICS) therapy.…”

Section: Development Of Targeted Therapymentioning

confidence: 99%

See 1 more Smart Citation

Emerging Role of Precision Medicine in Diagnosis and Treatment of Chronic Respiratory Disease

Wesnawa,

Asmara,

Supadmanaba

2024

View full text Add to dashboard Cite

Precision medicine is the current approach to managing chronic respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). It involves the evaluation of genetic, environmental, and lifestyle variations for each patient. It requires valid and specific biomarkers obtained through genetic studies, biomolecular technology, and omics-based technology to determine targeted therapies. Asthma and COPD have heterogeneous clinical phenotype variations, and giving one standard treatment for asthma and COPD may not necessarily provide the same effectiveness to other patients. The endotype, a specific molecular mechanism in disease pathogenesis, is essential in phenotype variation. The role of precision medicine in asthma and COPD is to determine endotypes through specific biomarkers and to provide specific targeted therapy for achieving personalized treatment in each patient. The application of precision medicine not only provides precise diagnosis and treatment but also enables early detection in individuals at risk and prevention of progression and exacerbation in asthma and COPD.

show abstract

Section: Understanding Genetics and Molecules In Pathogenesismentioning

confidence: 99%

Section: Development Of Targeted Therapymentioning

confidence: 99%

Emerging Role of Precision Medicine in Diagnosis and Treatment of Chronic Respiratory Disease

Wesnawa,

Asmara,

Supadmanaba

2024

View full text Add to dashboard Cite

show abstract

“…Airway bacterial load is a key component in the pathophysiology of CBI in patients with bronchiectasis [49] and other chronic inflammatory diseases [5,50]. It has been demonstrated that a high bacterial load is associated with increased local and systemic inflammation, more severe disease and poorer clinical outcomes.…”

Section: Microbiological Issuesmentioning

confidence: 99%

“…Although the use of aerosol therapy as a treatment for respiratory diseases dates back to ancient civilizations, it has now become the modality of choice for the administration of drugs that require direct action on the lower airways, as this type of therapy produces greater local deposition and is associated with fewer secondary effects than systemic administration. The presence of chronic bronchial inflammation [1][2][3] and infection [4,5] in both steady-state and exacerbation periods [6][7][8] of some airway diseases such as bronchiectasis, cystic fibrosis or COPD were determined as hard to treat and have been associated with a poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

Rosa

Suárez-Cuartín

Sibila

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.

show abstract

“…These symptoms mostly comprise chronic productive cough (usually with a purulent component) and multiple exacerbations of an infectious profile as well as chronic bronchial infection over the course of the disease's natural history [2][3][4][5]. The airway inflammation usually observed in bronchiectasis is mixed, with a predominance of neutrophils [6], although some patients may also present an increase in eosinophils [7][8][9]. Bronchiectasis can be caused by underlying pulmonary and extra-pulmonary diseases [10].…”

Section: Introductionmentioning

confidence: 99%

Etiology of Bronchiectasis in the World: Data from the Published National and International Registries

Gómez-Olivas,

Oscullo,

Martínez-García

2023

JCM

View full text Add to dashboard Cite

Bronchiectasis is the third leading chronic inflammatory disease of the airway caused by dozens of pulmonary and extra-pulmonary diseases. Infection by pathogenic microorganisms is very common. We aimed to analyze, for the first time in the literature, the etiology of bronchiectasis throughout the world via data published in national and international registries. A bibliographic search was carried out in PubMed and Web of Science. Seven studies were included, with a total of 27,258 patients from 33 countries of four continents. The most frequent cause of bronchiectasis was post-infectious: 30.5% (range: 19.1–40.4%), followed by idiopathic: 28.7% (18.5–38.1%). Post-tuberculous bronchiectasis accounted for 14.1% (1.8–35.5%), while etiologies associated with COPD and asthma comprised 7% (3.4–10.9%) and 5.2% (2.5–7.8%). In conclusion, there was a high degree of heterogeneity in the relative percentages of the main causes of bronchiectasis in the world, although post-infectious and idiophatic bronchiectasis continue to be the most frequent causes.

show abstract

Biomarcadores biológicos en las enfermedades respiratorias

Cited by 24 publications

References 181 publications

Emerging Role of Precision Medicine in Diagnosis and Treatment of Chronic Respiratory Disease

Emerging Role of Precision Medicine in Diagnosis and Treatment of Chronic Respiratory Disease

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

Etiology of Bronchiectasis in the World: Data from the Published National and International Registries

Contact Info

Product

Resources

About